Seneca Biopharma (SNCA) Stock Price, News & Analysis

Company Overview

Seneca Biopharma, Inc., a clinical stage biopharmaceutical company, develops novel treatments for diseases of high unmet medical needs. The company's stem cell-based technology enables the isolation and expansion of human neural stem cells from various areas of the developing human brain and spinal cord enabling the generation of physiologically relevant human neurons of various types. It is developing NSI-566, which has completed Phase II clinical trial for treating amyotrophic lateral sclerosis disease, as well as in Phase II clinical trial for the treatment of chronic ischemic stroke and in Phase I clinical trial for the treatment of chronic spinal cord injury; and NSI-189 that has completed Phase II clinical trials for the treatment of major depressive disorder. The company was formerly known as Neuralstem, Inc. and changed its name to Seneca Biopharma, Inc. in October 2019. Seneca Biopharma, Inc. was founded in 1996 and is headquartered in Germantown, Maryland.

Key Stats

• Today's Range: $2.20 to $2.46
• 50-Day Range: $1.39 to $10.25
• 52-Week Range: $0.50 to $2.67
• Volume: 51,920 shs
• Average Volume: 3.78 million shs
• Market Capitalization: $38.05 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

SNCA Stock Analysis - Frequently Asked Questions

What other stocks do shareholders of Seneca Biopharma own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Seneca Biopharma investors own include iBio (IBIO), Ocugen (OCGN), Onconova Therapeutics (ONTX), Tonix Pharmaceuticals (TNXP), Bionano Genomics (BNGO) and Artelo Biosciences (ARTL).

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Biological Products, Except Diagnostic
• Sub-Industry: N/A
• Current Symbol: NASDAQ:SNCA
• CUSIP: N/A
• CIK: N/A
• Web: www.senecabio.com
• Phone: (301) 366-4960
• Fax: N/A
• Employees: 7
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-8,350,000.00
• Net Margins: -230.34%
• Pretax Margin: N/A
• Return on Equity: -122.20%
• Return on Assets: -110.61%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 14.96
• Quick Ratio: 14.96

Sales & Book Value

• Annual Sales: $10,000.00
• Price / Sales: 3,805.12
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.33 per share
• Price / Book: 1.65

Miscellaneous

• Outstanding Shares: 17,296,000
• Free Float: N/A
• Market Cap: $38.05 million
• Optionable: Not Optionable
• Beta: 1.83